{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:00:00Z","timestamp":1780981200366,"version":"3.54.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Coronary heart disease (CHD) is the leading cause of mortality in China, yet the alignment between pharmaceutical research investment and clinical therapeutic priorities remains uncharacterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a dual-stream analysis. Stream A (Bibliometric): systematic searches of PubMed, Embase, Scopus, and Web of Science yielded 12,032 records; after deduplication and screening, 3,339 publications met inclusion criteria. Stream B (Clinical Trials): searches of CDCTP and ChiCTR identified 1,433 interventional drug trials after deduplication and quality control. Drugs were standardized to the WHO ATC classification; TCM ingredients to TCMID 2.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CHD research output expanded exponentially: Publications increased from 41 (2006) to 353 (2020; 760% increase), with 265 in 2025 (546% increase from baseline). Strikingly, 76.4% of trials were bioequivalence studies, with chemical pharmaceuticals dominating (78.6%) over traditional Chinese medicine (21.4%); calcium channel blockers comprised the largest drug category (45.9%. Notably, Critical gaps emerged: genomic research concentrated on inflammatory biomarkers (CRP, IL6, TNF; 25.8% of gene associations) while lipid metabolism targets were underrepresented (12.4%) despite statin therapeutic dominance; publication venue prestige demonstrated inverse volume-impact correlation (19.7% Q1 vs. 33.6% Q3 journals). Thus, quantitative expansion (compound annual growth rate (CAGR) 10.4%) coexisted with qualitative ceiling effects and target-drug mismatches between research investment and clinical guideline priorities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>China\u2019s CHD research landscape is policy-driven rather than clinically aligned: generic bioequivalence validation dominates (76.4%) while innovative therapeutic development and high-impact dissemination lag. Strategic rebalancing toward lipid metabolism genomic discovery, Phase II-III novel drug trials, and Q1 journal publication is imperative to bridge the research-clinical practice gap and align with global cardiovascular science standards.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1809277","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:31:53Z","timestamp":1780979513000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical analysis of drug treatment trends for coronary heart disease in China"],"prefix":"10.3389","volume":"13","author":[{"given":"Xu","family":"Li","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Surgery, Affiliated Hospital of North Sichuan Medical College, Sichuan","place":["Nanchong, China"]},{"name":"School of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Lou","sequence":"additional","affiliation":[{"name":"School of Ophthalmology and Optometry, North Sichuan Medical College","place":["Nanchong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Li","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Li","sequence":"additional","affiliation":[{"name":"School of Imaging, North Sichuan Medical College","place":["Nanchong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxian","family":"Gu","sequence":"additional","affiliation":[{"name":"School of Imaging, North Sichuan Medical College","place":["Nanchong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Die","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Stomatology, North Sichuan Medical College","place":["Nanchong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zining","family":"Luo","sequence":"additional","affiliation":[{"name":"School of Stomatology, North Sichuan Medical College","place":["Nanchong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Cao","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiebin","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Affiliated Hospital of North Sichuan Medical College, Sichuan","place":["Nanchong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/eurjpc\/zwae281","article-title":"Global burden of cardiovascular diseases: projections from 2025 to 2050.","volume":"32","author":"Chong","year":"2025","journal-title":"Eur J Prevent Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1016\/S0140-6736(25)01586-7","article-title":"Contemporary, non-invasive imaging diagnosis of chronic coronary artery disease.","volume":"406","author":"van der Bijl","year":"2025","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"ITC145","DOI":"10.7326\/ANNALS-25-03512","article-title":"Chronic coronary artery disease.","volume":"178","author":"Kittleson","year":"2025","journal-title":"Ann Intern Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1016\/S0140-6736(24)01446-6","article-title":"The burden of diseases, injuries, and risk factors by state in the USA, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.","volume":"404","year":"2024","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa2206916","article-title":"Global effect of modifiable risk factors on cardiovascular disease and mortality.","volume":"389","author":"Magnussen","year":"2023","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1016\/S0140-6736(21)00684-X","article-title":"The lancet women and cardiovascular disease commission: reducing the global burden by 2030.","volume":"397","author":"Vogel","year":"2021","journal-title":"Lancet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"105778","DOI":"10.1016\/j.ebiom.2025.105778","article-title":"Long-term outcomes of patients with pre-existing coronary artery disease after SARS-CoV-2 infection.","volume":"116","author":"Hadidchi","year":"2025","journal-title":"EBioMedicine"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1535182","DOI":"10.3389\/fphar.2025.1535182","article-title":"Inflammation and platelet hyperresponsiveness in coronary artery disease and the influence of Talin-1\/\u03b1IIb\u03b23-mediated bidirectional signaling pathway.","volume":"16","author":"Shi","year":"2025","journal-title":"Front Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"105616","DOI":"10.1016\/j.ebiom.2025.105616","article-title":"A framework for detecting causal effects of risk factors at an individual level based on principles of Mendelian randomisation: applications to modelling individualised effects of lipids on coronary artery disease.","volume":"113","author":"Shi","year":"2025","journal-title":"EBioMedicine"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1097\/CM9.0000000000003902","article-title":"2024 annual report on cardiovascular health and diseases in China: data and trend.","volume":"138","author":"Liu","year":"2025","journal-title":"Chin Med J (Engl)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"105325","DOI":"10.1016\/j.chemphyslip.2023.105325","article-title":"Recent advances in regulating lipid metabolism to prevent coronary heart disease.","volume":"255","author":"Du","year":"2023","journal-title":"Chem Phys Lipids"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1136\/heartjnl-2014-306463","article-title":"Gender differences in coronary heart disease.","volume":"102","author":"Khamis","year":"2016","journal-title":"Heart"},{"key":"B13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/07315724.2017.1381053","article-title":"Recent science and clinical application of nutrition to coronary heart disease.","volume":"37","author":"Houston","year":"2018","journal-title":"J Am Coll Nutr"},{"key":"B14","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.jacc.2019.04.068","article-title":"From ACE inhibitors\/ARBs to ARNIs in coronary artery disease and heart failure (part 2\/5).","volume":"74","author":"Leong","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jacc.2010.08.631","article-title":"Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial.","volume":"57","author":"Suh","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"105966","DOI":"10.1016\/j.ebiom.2025.105966","article-title":"Integrating multi-modal omics to identify therapeutic atherosclerosis pathways for coronary heart disease.","volume":"121","author":"de Ruiter","year":"2025","journal-title":"EBioMedicine"},{"key":"B17","doi-asserted-by":"publisher","first-page":"105518","DOI":"10.1016\/j.ebiom.2024.105518","article-title":"Simplifying coronary artery disease risk stratification: development and validation of a questionnaire-based alternative comparable to clinical risk tools.","volume":"111","author":"Kokkorakis","year":"2025","journal-title":"EBioMedicine"},{"key":"B18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1146\/annurev-med-050423-085207","article-title":"Medical therapy alone, percutaneous coronary intervention, or coronary artery bypass grafting for treatment of coronary artery disease.","volume":"76","author":"Amponsah","year":"2025","journal-title":"Annu Rev Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/S0140-6736(21)02334-5","article-title":"Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis.","volume":"398","author":"Sabatine","year":"2021","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(18)30423-9","article-title":"Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data.","volume":"391","author":"Head","year":"2018","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1097\/MCA.0000000000001381","article-title":"Effectiveness of low-dose rivaroxaban in preventing recurrent major adverse cardiovascular events in coronary artery disease: a systematic review and meta-analysis of randomized controlled trials.","volume":"35","author":"Al Hennawi","year":"2024","journal-title":"Coron Artery Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0212907","DOI":"10.1371\/journal.pone.0212907","article-title":"Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: systematic review and meta-analysis.","volume":"14","author":"Turgeon","year":"2019","journal-title":"PLoS One"},{"key":"B23","doi-asserted-by":"publisher","first-page":"118242","DOI":"10.1016\/j.socscimed.2025.118242","article-title":"The impact of bioequivalence regulation on pharmaceutical firm outcomes: evidence from China.","volume":"380","author":"Shen","year":"2025","journal-title":"Soc Sci Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1057817","DOI":"10.3389\/fnins.2022.1057817","article-title":"East Wind, West Wind: toward the modernization of traditional Chinese medicine.","volume":"16","author":"Yag\u00fce","year":"2022","journal-title":"Front Neurosci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1001\/jama.2015.7515","article-title":"Guideline-based statin eligibility, coronary artery calcification, and cardiovascular events.","volume":"314","author":"Pursnani","year":"2015","journal-title":"JAMA"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.","volume":"397","year":"2021","journal-title":"Lancet."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.1093\/eurheartj\/ehac309","article-title":"Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial.","volume":"43","author":"Hori","year":"2022","journal-title":"Eur Heart J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"628","DOI":"10.21037\/acs.2018.08.01","article-title":"Dual antiplatelet therapy versus aspirin monotherapy in diabetics with stable ischemic heart disease undergoing coronary artery bypass grafting.","volume":"7","author":"Mori","year":"2018","journal-title":"Ann Cardiothorac Surg"},{"key":"B29","doi-asserted-by":"publisher","first-page":"173114","DOI":"10.1016\/j.ejphar.2020.173114","article-title":"Statins and PCSK9 inhibitors: a new lipid-lowering therapy.","volume":"878","author":"Gallego-Colon","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e105597","DOI":"10.1136\/bmjopen-2025-105597","article-title":"Effectiveness of an AI-enhanced management system for coronary heart disease (AIM-CHD): rationale and design of a single-centre, open-label, randomised, parallel-controlled trial.","volume":"15","author":"Ba","year":"2025","journal-title":"BMJ Open"},{"key":"B31","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/jgs.18681","article-title":"Mapping potentially inappropriate medications in older adults using the Anatomical Therapeutic Chemical (ATC) classification system.","volume":"72","author":"Ndai","year":"2024","journal-title":"J Am Geriatr Soc"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e30581","DOI":"10.1002\/jcb.30581","article-title":"PCSK9 inhibitors as safer therapeutics for atherosclerotic cardiovascular disease (ASCVD): pharmacophore design and molecular dynamics analysis.","volume":"125","author":"Kehinde","year":"2024","journal-title":"J Cell Biochem"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1093\/eurjpc\/zwaf123","article-title":"Challenges in achieving LDL cholesterol targets and novel approaches to lipid lowering.","volume":"32","author":"Malick","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1038\/sj.bjc.6604405","article-title":"The impact of cancer research: how publications influence UK cancer clinical guidelines.","volume":"98","author":"Lewison","year":"2008","journal-title":"Br J Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/asi.21232","article-title":"The impact factor\u2019s Matthew Effect: a natural experiment in bibliometrics.","volume":"61","author":"Larivi\u00e8re","year":"2009","journal-title":"J Am Soc Inform Sci Technol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1093\/ije\/dyr120","article-title":"China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up.","volume":"40","author":"Chen","year":"2011","journal-title":"Int J Epidemiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.jacc.2018.07.079","article-title":"Genomic risk prediction of coronary artery disease in 480,000 adults: implications for primary prevention.","volume":"72","author":"Inouye","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1093\/eurheartj\/ehac093","article-title":"A polygenic risk score improves risk stratification of coronary artery disease: a large-scale prospective Chinese cohort study.","volume":"43","author":"Lu","year":"2022","journal-title":"Eur Heart J"},{"key":"B39","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1136\/heartjnl-2022-321657","article-title":"Impact of cardiovascular health and genetic risk on coronary artery disease in Chinese adults.","volume":"109","author":"Cui","year":"2023","journal-title":"Heart"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.19540\/j.cnki.cjcmm.20231018.501","article-title":"[Guidelines for economic evaluation of post-marketing Chinese patent medicine].","volume":"49","author":"Shi","year":"2024","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.23736\/S0026-4806.24.09283-8","article-title":"Efficacy and safety of Chinese herbal medicine Danshen in the treatment of coronary heart disease.","volume":"4","author":"Chen","year":"2024","journal-title":"Minerva Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e055263","DOI":"10.1136\/bmjopen-2021-055263","article-title":"Efficacy and safety of Ginkgo biloba dropping pills in the treatment of coronary heart disease with stable angina pectoris and depression: study protocol for a randomised, placebo-controlled, parallel-group, double-blind and multicentre clinical trial.","volume":"13","author":"Wu","year":"2023","journal-title":"BMJ Open"},{"key":"B44","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1142\/S0192415X25500284","article-title":"Modulation of NLRP3 inflammasome: advantages of Chinese herbal medicine in treating myocardial ischemia\/reperfusion injury.","volume":"53","author":"Du","year":"2025","journal-title":"Am J Chin Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"154749","DOI":"10.1016\/j.phymed.2023.154749","article-title":"Regulation of phospholipid peroxidation signaling by a traditional Chinese medicine formula for coronary heart disease.","volume":"114","author":"Ma","year":"2023","journal-title":"Phytomedicine"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1578783","DOI":"10.3389\/fphar.2025.1578783","article-title":"Therapeutic potential of Chinese herbal medicine for coronary heart disease patients with cerebral ischemic stroke: a systematic review and meta-analysis.","volume":"16","author":"Du","year":"2025","journal-title":"Front Pharmacol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1643611","DOI":"10.3389\/fphar.2025.1643611","article-title":"The clinical efficacy of herbal medicines containing leeches in the treatment of coronary heart disease: a systematic review and meta-analysis.","volume":"16","author":"Ziyuan","year":"2025","journal-title":"Front Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1499786","DOI":"10.3389\/fphar.2025.1499786","article-title":"Effects of Chinese medicine on modulating interleukin-17-regulated macrophages in coronary heart disease.","volume":"16","author":"Liu","year":"2025","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1809277\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:32:02Z","timestamp":1780979522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1809277\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":48,"alternative-id":["10.3389\/fmed.2026.1809277"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1809277","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"article-number":"1809277"}}